MorphoSys Inc (MOR) - Price-to-Projected Revenue Ratio
The market has already priced in the acquisition of MorphoSys AG (MOR) due to expectations surrounding its myelofibrosis drug. The business remains independent of GDP cycles, relying instead on clinical progress. Patent protection of molecules ensures a temporary monopoly. The company's projected P/S ratio helps assess valuation risks, while 12.90 serves as the current parameter value on this chart.
Analytical breakdowns for MorphoSys AG
- market price and analyst price targets:
- market capitalization indicators:
- book value of equity indicators:
- debt burden and liquidity indicators:
- financial results and valuation multiples details:
MOR - Net Profit|Projected Future Earnings MorphoSys AG|MOR - Market Cap to Net Income Ratio|Future Price to Earnings MorphoSys Corp|MOR - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MorphoSys Corporation|MOR - Profit before interest, taxes and amortization|Earnings per share for the last twelve months MorphoSys|MOR - Earnings per share for the trailing year|Quarterly EPS earnings growth morphosys.com|MOR - Net earnings per share growth this year|Earnings growth forecast for next year MorphoSys AG
- company sales and revenue statistics:
Initial company analysis:MOR (MorphoSys)
The forward P/S reflects the ratio of MorphoSys AG (MOR) market capitalization to projected revenue, allowing for an assessment of the growth premium amid liquidity volatility. By analyzing the projected P/S of MorphoSys AG (MOR) on the GURU.Markets platform, an investor can compare the business valuation with the monetization potential of the HuCAL library via royalties, which determines the fundamental fairness of the asset's current quotes.
Analysis of competing companies
Price-to-Projected Revenue Ratio BeiGene ONC|Forward Price to Sales HALO|RVMD - Price-to-Projected Revenue Ratio|Future Price to Revenue AAPG|CGON: Forward P/S Multiple|urogen.com - Forward Price to Sales|Price-to-Projected Revenue Ratio Bicara Therapeutics|Market Cap to Future Revenue Ratio Personalis Inc PSNL|Price-to-Projected Revenue Ratio Erasca Corp (ERAS)|Market Cap to Expected Sales Ratio Delcath Corp|Y-mAbs Therapeutics - Forward Price-to-Revenue Multiple|aurabiosciences.com (AURA) - Market Cap to Future Revenue Ratio|CADL - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Accuray Inc ARAY|SLS (sellaslifesciences.com) - Forward Price-to-Revenue Multiple|Actuate Therapeutics Inc - Forward Price to Sales|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|Forward P/S Multiple TuHURA|Forward P/S Multiple TARA|Fate Therapeutics Inc (FATE) - Projected Price to Revenue|Price-to-Projected Revenue Ratio Aadi Bioscience WHWK|TCRX - Forward Price-to-Revenue Multiple|CSBR - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio XBiotech Inc.|cel-sci.com (CVM) - Price-to-Projected Revenue Ratio|OS Therapies Inc. - Forward Price to Sales|RADX (Radiopharm Theranostics Limited) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Artiva (ARTV)|Forward P/S Multiple ANL|Forward P/S Multiple verupharma.com (VERU)|Price-to-Projected Revenue Ratio Tempest Therapeutics, Inc. TPST|XLO: Market Cap to Projected Revenue|Enochian BioSciences - Forward P/S Multiple|Mural Oncology plc (MURA) - Forward Price-to-Revenue Multiple|KAPA: Forward P/S Multiple|Market Cap to Future Revenue Ratio OnKure Therapeutics (OKUR)|Price-to-Projected Revenue Ratio CytoMed Therapeutics Ltd|CRIS: Forward Price to Sales|Forward Price-to-Revenue Multiple APLM (Apollomics, Inc.)|THAR (Tharimmune Corporation) - Forward Price to Sales|Forward P/S Multiple ADVB (Advanced Biomed)|GNPX - Forward Price-to-Revenue Multiple|CLDI: Forward Price-to-Revenue Multiple|SBFM - Forward P/S Multiple|xeneticbio.com (XBIO) - Price-to-Projected Revenue Ratio|Salarius Pharma - Forward Price to Sales|PPBT (Purple Biotech) - Forward P/S Multiple|Market Cap to Future Revenue Ratio AON AONC|Price-to-Projected Revenue Ratio BeiGene (BGNE)|Forward Price-to-Revenue Multiple Checkpoint Therapeutics Inc. CKPT|Price-to-Projected Revenue Ratio Elevation Oncology, Inc. ELEV|iCAD Inc. (ICAD) - Market Cap to Future Revenue Ratio|IKNA - Price-to-Projected Revenue Ratio|Forward Price to Sales NTBL (notablelabs.com)|viracta.com (VIRX) - Price-to-Projected Revenue Ratio|Future Price to Revenue NAYA (NAYA Biosciences Inc)|AAPGV (Ascentage Pharma Group Ltd) - Forward P/S Multiple
